# CDXS — Codexis Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** CDXS  
**Sources:** 25  
**Published:** 2026-10-17  
**Canonical:** https://app.k3vl4r.com/research/deep-research-cdxs-codexis-inc-catalysts-narrative-risks-7985

---

# Codexis Inc. (NASDAQ: CDXS) — Research Notes as of 2026-10-17

*Point-in-time findings from the sources below. Not investment advice.*

## Company Snapshot
Codexis is a Redwood City, California–based protein-engineering/biocatalysis company (founded 2002, IPO'd 2010) that runs two platforms: the **CodeEvolver** directed-evolution/AI engine and the **ECO Synthesis** RNA-manufacturing platform for siRNA [[3]](https://ir.codexis.com/news-events/press-releases/detail/452/codexis-reports-second-quarter-2026-financial-results)[[14]](https://stockanalysis.com/stocks/cdxs/)[[22]](https://en.wikipedia.org/wiki/Codexis)[[26]](https://ir.codexis.com/company-information). It reports in two segments — Performance Enzymes (pharma biocatalysis) and Novel Biotherapeutics (RNA) [[18]](https://stocktwits.com/symbol/CDXS). Market data as of the Oct 16, 2026 close: stock price ~$1.24, down roughly −24% YTD and about −53% over the trailing year, versus a 52-week range of ~$0.96–$2.98 and a beta of 2.55 [[9]](https://tickernerd.com/stock/cdxs-forecast/)[[14]](https://stockanalysis.com/stocks/cdxs/)[[16]](https://finance.yahoo.com/quote/CDXS/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-cdxs-codexis-inc-catalysts-narrative-risks-7985 (free to sign up)._
